Timed Creatinine Clearance and Measured Glomerular Filtration Rate in Living Kidney Donors

S. Ali Husain, MD, Jacob S. Stevens, MD, Kristen L. King, MPH, Shelief Y. Robbins-Juarez, MD, Matthew Cohen, MD, Alexander K. Lyashchenko, MD, Serge Cremers, PhD, PharmD, Sumit Mohan, MD

PII: S2590-0595(22)00205-9
DOI: https://doi.org/10.1016/j.xkme.2022.100572
Reference: XKME 100572

To appear in: Kidney Medicine

Received Date: 5 August 2022
Accepted Date: 18 September 2022

Please cite this article as: Husain SA, Stevens JS, King KL, Robbins-Juarez SY, Cohen M, Lyashchenko AK, Cremers S, Mohan S, Timed Creatinine Clearance and Measured Glomerular Filtration Rate in Living Kidney Donors, Kidney Medicine (2022), doi: https://doi.org/10.1016/j.xkme.2022.100572.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.
Timed Creatinine Clearance and Measured Glomerular Filtration Rate in Living Kidney Donors

To the Editor:

Assessment of pre-donation glomerular filtration rate (GFR) is a key aspect of the evaluation of potential living kidney donors. In the United States, measurement of donor GFR is a regulatory requirement and most commonly assessed using 24-hour timed creatinine clearance (CrCl$_{24}$), despite the potential for error due to incorrectly timed urine sample collection and tubular creatinine secretion.\textsuperscript{1,2} We aimed to determine the real-world performance of CrCl$_{24}$ in living donor candidates.

We performed a retrospective cross-sectional study of living kidney donor candidates evaluated at our center. This study was approved by the Columbia University Medical Center institutional review board (#AAA11288). We identified 279 consecutive candidates who underwent cold iothalamate clearance testing from 2018-2021 for GFR assessment as part of living kidney donation evaluation. At our center, a GFR $\geq$80ml/min/1.73m$^2$ is used to determine suitability for donation for most candidates. Donor candidates were referred for iothalamate clearance testing if either CKD-EPI2009 creatinine-based estimated GFR (eGFR) or CrCl$_{24}$ were <90mL/min/1.73m$^2$, if the candidate was unable to perform a timed urinary collection, or if the testing was requested by the evaluating nephrologist. After excluding donors with incomplete data (see detailed methods in Item S1), we analyzed a final cohort of 212 donor candidates.

Demographic information was obtained from the medical record. Body surface area (BSA) was calculated using the Gehan & George formula.\textsuperscript{3} Donor candidates performed ambulatory 24-hour urine collections, and CrCl$_{24}$ was calculated as the
product of 24-hour urinary creatinine concentration and urine volume divided by serum creatinine concentration, then adjusted for BSA. Serum creatinine and cystatin C values were used to calculate eGFR using the CKD-EPI2021 combined creatinine and cystatin C equation (eGFR_crcys). 4 “Measured” GFR (mGFR) was determined based on cold iothalamate clearance using the Bröchner-Mortensen correction and adjusted for BSA (Item S1). 5 Bias for each GFR estimate equation was calculated as [mGFR - estimate]. All GFR and bias values below are presented in units ml/min/1.73m².

Among 212 donor candidates analyzed, median age was 54 years, and 62% were female. Body size parameters are presented in Table 1. Median mGFR was 107 (IQR 95-120). Median weight-indexed 24-hour creatinine excretion was 21.9mg/kg (16.5-26.0) for males and 15.9 (12.8-18.7) for females, and median CrCl₂₄ was 73 (58-89). Median serum creatinine was 0.89mg/dL and median cystatin C was 0.8mg/L, corresponding to median eGFR_crcys 97 (IQR 85-111). Scatterplots of mGFR versus CrCl₂₄ and eGFR_crcys are shown in Figure 1. Overall, median bias for CrCl₂₄ was 33.9 (IQR 16.3-50.7), including 40.0 (20.5-63.3) for males and 32.1 (14.2-46) for females. Median bias for eGFR_crcys was 10.5 (IQR -1.7 to 25.4), including 25.6 (13.4-36.0) for males and 2.7 (-11.0 to 13.6) for females.

Using a GFR-based donation eligibility threshold of 80, 119 (56%) donors had discordant classification using CrCl₂₄ versus mGFR (Table S1). Of these, 115 (54% of all candidates and 97% of those with discordant classification) had mGFR≥80 but CrCl₂₄<80, likely a reflection of the underlying selection bias of the cohort.

We next sought to determine whether urine collection adequacy (as reflected by weight-indexed 24-hour creatinine excretion) or similarity in CrCl₂₄ and eGFR_crcys results
could be used as indicators of low CrCl$_{24}$ bias. Among males with creatinine excretion 20-25mg/kg (n=23) and females with creatinine excretion 15-20mg/kg (n=49), median bias was 32.2 (IQR 14.5-46.7) (Figure S1).

Only 70 (33%) candidates had eGFR$_{crcys}$ within 20% of CrCl$_{24}$. Although there was a positive relationship between the absolute bias of CrCl$_{24}$ and the absolute difference between CrCl$_{24}$ and eGFR$_{crcys}$ ($r^2$=0.34, p<0.001, Figure 1, Figure S2), CrCl$_{24}$ bias remained high even when the difference between both estimates was small: Even among the 89 donor candidates with eGFR$_{crcys}$ within 20 ml/min/1.73m$^2$ of CrCl$_{24}$, median bias was 22.1 (IQR 11.5 - 37.2), suggesting that similarity between CrCl$_{24}$ and eGFR$_{crcys}$ does not imply that CrCl$_{24}$ approximates mGFR well.

Given the large median bias we observed, CrCl$_{24}$ appears to be a suboptimal method of “measuring” GFR in a subset of potential living kidney donors despite current regulatory policies requiring GFR assessment using “isotopic methods or a creatinine clearance calculated from a 24-hour urine collection.”6 This inaccuracy likely stems from the challenges of accurately collecting timed urine samples in an ambulatory setting. Our study may be limited by selection bias, given that participants were healthy and only selected donor candidates were referred for iothalamate clearance testing, thereby enriching our cohorts for individuals with eGFR or CrCl that underestimated mGFR. Additionally, potential deviation of iothalamate-based mGFR from true GFR and may influence our results. However, given that CrCl$_{24}$ does not appear to accurately reflect GFR in a subset of candidates—and that CrCl$_{24}$ bias remained large even among those with creatinine excretion suggesting “adequate” urinary collection and those with agreement between CrCl$_{24}$ and eGFR$_{crcys}$ results—additional study is needed to
determine how to best evaluate kidney function during living kidney donor evaluations and identify which donor candidates may warrant more accurate GFR assessments.

S. Ali Husain, MD\textsuperscript{1,2}, Jacob S. Stevens, MD\textsuperscript{1,2}, Kristen L. King, MPH,\textsuperscript{1,2}, Shelif Y. Robbins-Juarez, MD,\textsuperscript{1} Matthew Cohen, MD,\textsuperscript{1} Alexander K. Lyashchenko, MD\textsuperscript{3}, Serge Cremers, PhD, PharmD\textsuperscript{3,4}, Sumit Mohan, MD\textsuperscript{1,25}

Supplementary Material

Figure S1. Bias of 24-hour timed creatinine clearance versus weight-indexed 24-hour creatinine excretion.

Figure S2. Absolute value of the bias of 24-hour timed creatinine clearance (CrCl24) versus the absolute difference between the 24-hour timed creatinine clearance and the estimated glomerular filtration rate based on the 2021 CKD-EPI creatinine-cystatin C equation (eGFRcrcys).

Item S1. Supplementary Methods

Table S1. Reclassification of glomerular filtrate rate (GFR) based donor eligibility using measured GFR versus timed creatinine clearance.

Descriptive Text for Online Delivery

Supplementary File (PDF)

Fig S1-S2, Item S1, Table S1

Article Information

Authors’ Affiliations: 1. Division of Nephrology, Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, New York, NY

2. The Columbia University Renal Epidemiology (CURE) Group, New York, NY
3. Department of Pathology and Cell Biology, Columbia University Irving Medical
Center, New York, NY

4. Department of Medicine, Columbia University College of Physicians & Surgeons,
New York, NY

5. Department of Epidemiology, Mailman School of Public Health, Columbia University
Address for Correspondence: S. Ali Husain, MD, MPH, MA
Division of Nephrology, Department of Medicine
622 W 168th St PH4-124, New York, NY, 10032

sah2134@cumc.columbia.edu

Authors’ Contributions: Research idea and study design: SAH, KLK, AKL, SC, SM;
Data acquisition: SAH, JSS, SYRJ, MC; Statistical analysis: SAH;
Data analysis/interpretation: SAH, JSS, KLK, SYRJ, MC, AKL, SC, SM; Supervision or
mentorship: AKL, SC, SM. Each author contributed important intellectual content during
manuscript drafting or revision and accepts accountability for the overall work by
ensuring that questions pertaining to the accuracy or integrity of any portion of the work
are appropriately investigated and resolved.

Support: SAH was supported by a Nelson Family Faculty Development Award and NIH
grant K23DK133729. SM was supported by NIH grants DK114893, DK116066,
DK126739, DK130058 and MD014161 and a Nelson Family Faculty Development
Award. The funders had no role in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; preparation, review, or approval of
the manuscript; and decision to submit the manuscript for publication.

Financial Disclosure: The authors declare that they have no relevant financial interests.
Peer Review: Received August 5, 2022 as a submission to the expedited consideration track with 2 external peer reviews. Direct editorial input from the Statistical Editor and the Editor-in-Chief. Accepted in revised form September 18, 2022.

References

Table 1. Characteristics of Donor Candidates Analyzed

<table>
<thead>
<tr>
<th></th>
<th>All (n=212)</th>
<th>Male (n=80)</th>
<th>Female (n=132)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>n (col%) or median (IQR)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>54 (43-61)</td>
<td>49 (37-58)</td>
<td>57 (47-62)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>138 (65)</td>
<td>46 (58)</td>
<td>92 (70)</td>
</tr>
<tr>
<td>Black/African American</td>
<td>19 (9)</td>
<td>11 (14)</td>
<td>8 (6)</td>
</tr>
<tr>
<td>All others</td>
<td>55 (26)</td>
<td>23 (29)</td>
<td>32 (24)</td>
</tr>
<tr>
<td>Height, cm</td>
<td>168 (163-175)</td>
<td>175 (170-180)</td>
<td>163 (159-170)</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>79 (66-88)</td>
<td>76 (63-85)</td>
<td>82 (74-93)</td>
</tr>
<tr>
<td>Body Mass Index, kg/m2</td>
<td>27 (24-31)</td>
<td>27 (24-30)</td>
<td>28 (24-32)</td>
</tr>
<tr>
<td>Body Surface Area, m2</td>
<td>2.06 (1.90-2.19)</td>
<td>2.16 (2.05-2.30)</td>
<td>1.98 (1.87-2.13)</td>
</tr>
<tr>
<td>24-hour creatinine excretion, g</td>
<td>1.29 (1.06-1.67)</td>
<td>1.75 (1.39-2.22)</td>
<td>1.16 (0.96-1.36)</td>
</tr>
<tr>
<td>Weight-indexed 24-hour creatinine excretion, mg/kg</td>
<td>17.4 (13.5-21.8)</td>
<td>21.9 (16.5-26.0)</td>
<td>15.9 (12.8-18.7)</td>
</tr>
<tr>
<td>Serum creatinine, mg/dL</td>
<td>0.89 (0.76-1.00)</td>
<td>1.07 (0.93-1.15)</td>
<td>0.81 (0.73-0.90)</td>
</tr>
<tr>
<td>Cystatin C, mg/L</td>
<td>0.8 (0.8-0.9)</td>
<td>0.8 (0.8-1.0)</td>
<td>0.8 (0.7-0.9)</td>
</tr>
<tr>
<td>GFR assessments, ml/min/1.73m2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measured GFR (iothalamate)</td>
<td>107 (95-120)</td>
<td>111 (100-123)</td>
<td>106 (91-117)</td>
</tr>
<tr>
<td>CKD-EPI 2021 (creatinine)</td>
<td>90 (77-104)</td>
<td>88 (79-103)</td>
<td>91 (76-104)</td>
</tr>
<tr>
<td>CKD-EPI 2012 (cystatin C)</td>
<td>99 (83-110)</td>
<td>105 (86-116)</td>
<td>98 (82-105)</td>
</tr>
<tr>
<td>CKD-EPI 2021 (combined)</td>
<td>97 (85-111)</td>
<td>85 (76-96)</td>
<td>106 (94-115)</td>
</tr>
<tr>
<td>Timed Creatinine Clearance</td>
<td>73 (58-89)</td>
<td>67 (54-86)</td>
<td>75 (63-89)</td>
</tr>
</tbody>
</table>

Abbreviations: GFR, glomerular filtration rate
Figure Legend

**Figure 1.** Measured glomerular filtration rate (GFR) versus 24-hour timed creatinine clearance (Panel A) and estimated GFR based on the CKD-EPI 2021 creatinine-cystatin C equation (eGFRcrcys) (Panel B). Red lines indicate 80 ml/min/1.73m2, a typical threshold used for suitability for living kidney donation.